Home » Pipeline
Pipeline
November 8, 2019
| Company | Drug/Device | Medical Condition | Status |
|---|---|---|---|
| BioCryst Pharmaceuticals, Inc. | BCX9250 | fibrodysplasia ossificans progressive (FOP) | Phase 1 trial initiated enrolling healthy subjects |
| Revolution Medicines, Inc. Amgen |
RMC-4630 in combination with AMG 510 | advanced solid tumors | Phase 1b trial initiated enrolling subjects with advanced solid tumors harboring the KRASG12C mutation |
| X4 Pharmaceuticals, Inc. | X4P-001 | Severe Congenital Neutropenia (SCN) | Phase 1b trial initiated enrolling 45 subjects with SCN and other selected congenital neutropenia disorders |
| CohBar, Inc. | CB4211 | nonalcoholic steatohepatitis (NASH), NAFLD and obesity | Phase 1b trial initiated enrolling 20 obese subjects with NAFLD |
| Cartesian Therapeutics | Descartes-08 | generalized myasthenia gravis (GMG) | Phase 1/2 trial initiated |
| Ichnos Sciences | ISC 27864 | osteoarthritic pain | Phase 2b trial initiated enrolling 624 adult subjects with moderate osteoarthritic pain of the knee and/or hip at sites in India. |
| Ichnos Sciences | ISB 830 | atopic dermatitis | Phase 2b trial initiated enrolling 312 adult subjects with moderate to severe atopic dermatitis at sites in the U.S., Canada and Europe |
| RhoVac AB | RV001 | prostate cancer | Phase 2b trial initiated enrolling 175 subjects at multiple centers in Denmark, Finland, Sweden, United Kingdom, Belgium, Germany and the U.S. |
| Biohaven Pharma Holding Company Ltd. | troriluzole | Alzheimer’s disease | Phase 2/3 trial initiated enrolling subjects with mild to moderate Alzheimer’s disease |
| CymaBay Therapeutics, Inc. | seladelpar | Primary Biliary Cholangitis (PBC) | Phase 3 trial initiated enrolling 240 subjects in over 20 countries |
| Revance Therapeutics, Inc. | DaxibotulinumtoxinA for Injection (DAXI) | isolated cervical dystonia (CD) | Phase 3 trial initiated enrolling 301 subjects at 60 sites in the U.S., Canada and Europe |
| EpicentRX, Inc. | RRx-001 | small cell lung cancer | Phase 3 trial initiated enrolling 126 subjects with third-line and beyond small cell lung cancer |
| Okami Medical Inc. | LOBO Vascular Occlusion System | occlusion of peripheral blood vessels | 510(k) approval granted by the FDA |
| Autolus Therapeutics plc | AUTO1 | acute lymphoblastic leukemia (ALL) | Orphan drug designation granted by the FDA |
| Sanofi | Fluzone High-Dose Quadrivalent (Influenza Vaccine) | prevention of influenza disease caused by influenza A and B strains contained in the vaccine in subjects 65 years of age and older | sBLA approval granted by the FDA |
| RedHill Biopharma Ltd. | Talicia (omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg | Helicobacter pylori (H. pylori) infection in adults | Approval granted by the FDA |
| GE Healthcare | Clariscan | intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity | Approval granted by the FDA |
| Crescita Therapeutics Inc. | Pliaglis (enhanced formulation) | superficial dermatological procedures | Approval granted by the FDA |
| Sandoz | Ziextenzo (pegfilgrastim) | infection in cancer patients | Approval granted by the FDA |
